Botulinum A toxin for cranial-cervical dystonia

Joseph Jankovic, Janet Orman

April 01, 1987; 37 (4) Articles

A double-blind, placebo-controlled study

First published April 1, 1987, DOI: https://doi.org/10.1212/WNL.37.4.616





Abstract

We studied the effects of botulinum A toxin in 12 patients with blepharospasm and 10 patients with oromandibular-cervical dystonia received in a double-blind manner. All blepharospasm patients improved, 71.6% on a clinical rating score, 60.7% by self-assessment, and 38.9% by video-rating; there was no improvement with placebo. The beneficial effects lasted a mean of 12.5 weeks (range, 5 to 28). Only 37.5% of the patients with oromandibular-cervical dystonia improved. Patients with pharyngeal dystonia and spasmodic dysphonia also improved.

• © 1987 by the American Academy of Neurology

You May Also be Interested in

Article

Dystonia & tremor: A cross-sectional study of the dystonia coalition cohort

Aasef G. Shaikh, Sinem Balta Beylergil, Laura Scorr, et al.

October 12, 2020

• Article

Regional, not global, functional connectivity contributes to isolated focal dystonia

Scott A. Norris, Aimee E. Morris, Meghan C. Campbell, et al.

September 10, 2020

•

1 of 1